72 results

Regulation Value

Posted on 10.06.2013

Specific Biological Properties Distinguish In Vitro Diagnostics

My first blog provided the necessary insight into in vitro diagnostics and their distinguishing characteristic of never directly coming in contact with the human body. So how do they work? What differentiates them from other medical devices you hear about? The answer is that vast majority of in vitro diagnostics (IVDs) rely on biological properties and materials in order to perform as intended.

By Maurizio Suppo EU IVD Representative at Assobiomedica


Posted on 05.06.2013

Women’s Health and IVDs – An Investigative Report

My background in women’s rights has driven me to look into how my current field of work has taken issues which affect women into account. So as an EDMA Communications Intern, I decided to dive into the field of in vitro diagnostics (IVDs) to identify whether the makers of IVDs have played a role in empowering women.  Here’s what my investigation revealed…

By Noreen Aldworth EDMA Communications Intern

Business Value

Posted on 23.05.2013

New rules, new markets – medical devices and diagnostics’ place in a changing Europe

Judging by the weather in Belgium (currently 10° and raining) you wouldn’t say it, but it’s almost summer. Well, at least according to the calendar. And apart from the supposed good weather, summer also brings with it a host of new information on the MedTech Forum. Speakers are being confirmed, registrations coming in and preparations being made. Less than 5 months from now, we will all be seeing each other again at the event no one in our industry can afford to miss. So what does the MedTech Forum hold in store this year.

By Serge Bernasconi Chief Executive Officer, MedTech Europe

Regulatory revision
Regulation Value

Posted on 24.04.2013

Getting regulation right for in vitro diagnostics and medical devices

It’s been a busy two weeks at the Parliament once again, with the release of both the draft report for the revision of the Medical Devices Directives (MDD) and that for the In Vitro Diagnostics Directives (IVDD) revision. Last Monday, EU Parliament Rapporteur Dagmar Roth-Behrendt published her draft report on the revision of the MDD. Although not surprised, we of course regret to see proposals such as a shift to centralised pre-market authorisation. This US-like system will not bring about the necessary additional patient safety and actually risks hindering patients in their access to lifesaving devices because of unnecessary delays in these devices becoming available to them.

By Serge Bernasconi Chief Executive Officer, MedTech Europe

European Parliament
Regulation Value

Posted on 20.03.2013

A tale of two workshops – A lively day at the European Parliament ENVI hearing

By now most of you will have noticed that we have launched our “Don’t Lose the 3”-campaign. (If you haven’t, watch the 1-minute video and patient stories here. The basic message of the campaign is that, thanks to our decentralised approval system for medical devices in Europe, Europeans have access to life-saving and life-enhancing technologies three to five years before US patients without compromising safety. This is also the message I brought forward during the 26 February hearing of the ENVI committee at the European Parliament.

By Serge Bernasconi Chief Executive Officer, MedTech Europe

Salt and heart failure

Posted on 13.03.2013

Tailored Tools for Diagnosing Heart Failure

As the 2013 World Salt Awareness Week calls for “Less Salt, Please”, it may be time for Europeans to seriously consider the implications of their seasoning habits on their health, notably their heart health. Heart failure (HF) is characterised by the inability of the heart to respond to the blood flow demands of the body, a condition that is becoming increasingly common, with more than 20 million directly affected worldwide.

By Damien Gruson Head, Department of Laboratory Medicine, St-Luc University Hospital

Time for revision
Regulation Value

Posted on 22.02.2013

All about meetings and events these days: ENVI hearing, Personalised Medicine and the 2013 MedTech Forum

“First one down”… And I have to admit that I was pleased to read all your positive feedback and comments. This really gives me the enthusiasm to do even better in this second blog. If there is one thing I’ve learned from this whole process, it is that starting a new blogpost is like having to wake up in the morning: at first when the alarm is still buzzing you wish you didn’t have to, but once you get that first leg out of bed, you’re happy you did and everything else sort of follows from that first step.

By Serge Bernasconi Chief Executive Officer, MedTech Europe

Blood test
Regulation Value

Posted on 20.02.2013

Understanding in Vitro Diagnostics & Why They Need a Separate Regulatory Framework

Many times I’ve found myself in situations where I had to explain that indeed in vitro diagnostics (IVDs) are to all extent medical devices but that, in practice, the subject we happened to be discussing would not entirely (or at all) be applicable to IVDs.
It was always a case of: “…yes, yes.. BUT”…
If there is one message you take away from this post, let it be… IVDs have very different risk sets associated to them: no direct contact with patient, value of the medical data they deliver and that they provide no treatment.

By Maurizio Suppo EU IVD Representative at Assobiomedica

Star blogging

Posted on 28.01.2013

What to expect from EDMA, Eucomed and MedTech Europe in 2013

Only a few days ago, I heard those words for the first time. Me? Writing a blog? Hmmm, ok, there could be an opportunity here… And now I am looking at a blinking cursor inviting me to put down a few thoughts and ideas.
Well, why don’t I start by answering a few questions “Why now? Why not 3-4 months ago, Serge? How often can we expect to read your posts? And what will you be talking about?”

By Serge Bernasconi Chief Executive Officer, MedTech Europe